Novel therapies in development for the treatment of traumatic brain injury
Vink, Robert, and Nimmo, Alan J. (2002) Novel therapies in development for the treatment of traumatic brain injury. Expert Opinion on Investigational Drugs, 11 (10). pp. 1-12.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1517/13543784.11.10...
In industrialised countries, the mean per capita incidence of traumatic brain injury (TBI) that results in a hospital presentation is 250 per 100,000. In Europe and North America alone, this translates to > 2 million TBI presentations annually. Approximately 25% of these presentations are admitted for hospitalisation. Despite the significance of these figures, there is no single interventional pharmacotherapy that has shown efficacy in the treatment of clinical TBI. This lack of efficacy in clinical trials may be due, in part, to the inherent heterogeneity of the traumatic brain injury population. However, it is the multifactorial nature of secondary injury that also poses a major hurdle, particularly for those therapies that have been designed to specifically target an individual injury factor. It is now becoming increasingly recognised that any successful TBI therapy may have to simultaneously affect multiple injury factors, somewhat analogous to other broad spectrum interventions. Recent efforts in experimental TBI have therefore focussed on developing novel pharmacotherapies that may affect multiple injury factors and thus improve the likelihood of a successful outcome. While a number of interventions are noteworthy in this regard, this review will focus on three novel compounds that show particular promise: magnesium, substance P antagonists and cyclosporin A.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||cyclosporin A; head injury; magnesium; neuropeptides; neuroprotection; neurotrauma; substance P|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1109 Neurosciences > 110903 Central Nervous System @ 34%|
11 MEDICAL AND HEALTH SCIENCES > 1109 Neurosciences > 110999 Neurosciences not elsewhere classified @ 33%
11 MEDICAL AND HEALTH SCIENCES > 1109 Neurosciences > 110905 Peripheral Nervous System @ 33%
|SEO Codes:||97 EXPANDING KNOWLEDGE @ 100%|
|Deposited On:||23 Dec 2010 11:21|
|Last Modified:||12 Feb 2011 20:23|
Last 12 Months: 0
Repository Staff Only: item control page